Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 6,775 Shares of Stock

Blueprint Medicines Corp (NASDAQ:BPMC) insider Kate Haviland sold 6,775 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.93, for a total transaction of $507,650.75. Following the completion of the transaction, the insider now owns 12,649 shares of the company’s stock, valued at $947,789.57. The sale was disclosed in a filing with the SEC, which is available at this link.

Blueprint Medicines Corp (NASDAQ:BPMC) opened at $82.55 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28. Blueprint Medicines Corp has a 12 month low of $32.43 and a 12 month high of $92.00.

Several research analysts have commented on BPMC shares. ValuEngine lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Raymond James Financial set a $82.00 price objective on shares of Blueprint Medicines and gave the stock a “buy” rating in a report on Sunday, December 10th. Wedbush restated an “outperform” rating and issued a $82.00 price objective (up from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. BidaskClub lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Finally, Zacks Investment Research lowered shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.20.

Several institutional investors have recently modified their holdings of BPMC. Perceptive Advisors LLC increased its stake in shares of Blueprint Medicines by 168.6% in the 4th quarter. Perceptive Advisors LLC now owns 1,140,434 shares of the biotechnology company’s stock worth $86,000,000 after acquiring an additional 715,773 shares in the last quarter. State Street Corp increased its stake in shares of Blueprint Medicines by 76.8% in the 2nd quarter. State Street Corp now owns 1,400,035 shares of the biotechnology company’s stock worth $70,936,000 after acquiring an additional 608,296 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in shares of Blueprint Medicines by 54.9% in the 3rd quarter. TimesSquare Capital Management LLC now owns 867,700 shares of the biotechnology company’s stock worth $60,453,000 after acquiring an additional 307,700 shares in the last quarter. Pictet Asset Management Ltd. increased its stake in shares of Blueprint Medicines by 103.7% in the 3rd quarter. Pictet Asset Management Ltd. now owns 603,942 shares of the biotechnology company’s stock worth $42,077,000 after acquiring an additional 307,504 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Blueprint Medicines by 16.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock worth $71,746,000 after acquiring an additional 195,517 shares in the last quarter. Institutional investors own 83.79% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/insider-selling-blueprint-medicines-corp-bpmc-insider-sells-6775-shares-of-stock/1885586.html.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million
Alex Cora Leading Effort by Red Sox to Deliver Puerto Rico Relief Supplies
Alex Cora Leading Effort by Red Sox to Deliver Puerto Rico Relief Supplies


Leave a Reply

 
© 2006-2018 BBNS.